Livmarli is named as an intervention in 2 current clinical trials in our USA and Japan registers. 2 are recruiting patients now. All registered phases are Observational. The sponsor with the most trials is Mirum Pharmaceuticals, Inc (1). The most-studied condition is Alagille Syndrome.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)
NCT06193928 · ClinicalTrials.gov ↗ · Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis
|
Observational | Recruiting | Mirum Pharmaceuticals, Inc | USA |
|
A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)
NCT07293897 · ClinicalTrials.gov ↗ · Alagille Syndrome (ALGS), Progressive Familial Intrahepatic Cholestasis (PFIC)
|
Observational | Recruiting | Takeda | Japan |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Mirum Pharmaceuticals, Inc | 1 |
| Takeda | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 1 | 1 |
| Clinical trials in Japan | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our USA and Japan registers name Livmarli as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 1 with sites in USA and 1 with sites in Japan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Mirum Pharmaceuticals, Inc (1) and Takeda (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Livmarli works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Livmarli works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Livmarli (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.